Endonovo Therapeutics Inc (ENDV)

[BlackDoggie]

It's poorly worded, but the answer is simple. For the purpose of clinical trials, pain is rated on a subjective scale - usually 1-10 or something like that. You're then comparing the change in pain rating for a treatment group (average) against the change in pain rating for a placebo/SOC control group (average). If the placebo/SOC group averages a 1-point decrease on the pain scale, and the treatment group averages a 3-point decrease, you have a 300% reduction in pain compared to the control group. Obviously, the average numbers would be measured in decimal places, making much smaller changes for the control group possible and making a 1000% reduction obtainable. Again, it was not worded particularly clearly in the PR, but that doesn't mean that it's wrong or illegitimate. The flipside is that to know how effective the treatment REALLY is, you need to know what sort of change it's being compared against. If the control group reports an average change of (0.01) on a scale of 1-10, then a 1000% reduction is only (0.1) and isn't going to impress anyone.

Regardless, happy to hear of the distribution deal. Great to see real progress on the commercialization side of the business. Hopefully this is the beginning of many good things to come.